David Dai

Stock Analyst at UBS

(0)
# 4944
Out of 5,270 analysts
21
Total ratings
12.50%
Success rate
-30.94%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
Immunocore Hldgs
Initiates Coverage On: Sell
24
28.89 -16.93% 1 Oct 24, 2024
Nuvalent
Initiates Coverage On: Neutral
100
71.01 40.83% 1 Oct 24, 2024
Blueprint Medicines
Initiates Coverage On: Neutral
88
89.66 -1.85% 1 Oct 24, 2024
Perspective Therapeu...
Initiates Coverage On: Buy
20
2.46 713.01% 1 Oct 24, 2024
Nurix Therapeutics
Initiates Coverage On: Buy
35
14.16 147.18% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
45.61 57.86% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
27
7.24 272.93% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
31.77 117.19% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
19.09 161.92% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
17
4.03 321.84% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
8 275% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
25.17 138.38% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
15.56 137.79% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.85 3194.12% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
13.5 196.3% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
2.29 1646.72% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
1.62 2986.42% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
40.22 29.29% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017